CNS
MCID: CNT035
MIFTS: 62

Central Nervous System Disease (CNS)

Categories: Immune diseases, Neuronal diseases

Aliases & Classifications for Central Nervous System Disease

MalaCards integrated aliases for Central Nervous System Disease:

Name: Central Nervous System Disease 12 15
Central Nervous System Diseases 44
Cns Diseases 55
Cns Disorder 73
Cns 48

Classifications:



External Ids:

Disease Ontology 12 DOID:331
ICD10 33 G96.9 G96 G96.8
MeSH 44 D002493
NCIt 50 C2934
SNOMED-CT 68 23853001
UMLS 73 C0007682

Summaries for Central Nervous System Disease

Disease Ontology : 12 A nervous system disease that affects either the spinal cord (myelopathy) or brain (encephalopathy) of the central nervous system.

MalaCards based summary : Central Nervous System Disease, also known as central nervous system diseases, is related to meningitis and neuromyelitis optica, and has symptoms including headache, hemiplegia and hyperexplexia. An important gene associated with Central Nervous System Disease is H19 (H19, Imprinted Maternally Expressed Transcript), and among its related pathways/superpathways are Neuroscience and IL-17 Family Signaling Pathways. The drugs Ritonavir and Sevoflurane have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and bone, and related phenotypes are cellular and behavior/neurological

CDC : 3 Bromobenzylcyanide (CA), Chloroacetophenone (CN), Chlorobenzylidenemalononitrile (CS), Chloropicrin (PS), Dibenzoxazepine (CR)

Wikipedia : 76 Central nervous system diseases, also known as central nervous system disorders, are a group of... more...

Related Diseases for Central Nervous System Disease

Diseases in the Nervous System Disease family:

Autoimmune Disease of Central Nervous System Congenital Nervous System Abnormality
Central Nervous System Disease Autoimmune Disease of the Nervous System

Diseases related to Central Nervous System Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 meningitis 32.5 IFNG IL1B MMP9
2 neuromyelitis optica 32.1 GFAP MBP MOG
3 nervous system disease 31.8 APP BACE1 BDNF CCR1 CXCR3 GFAP
4 demyelinating disease 31.1 IFNG IL1B MBP MMP9 MOG
5 autoimmune disease 30.9 CXCR3 IFNG IL1B MBP MOG
6 multiple sclerosis 30.7 BDNF CCR1 CXCR3 GFAP IFNG IL1B
7 alzheimer disease 30.6 APP BACE1 BDNF GFAP HAR1A IL1B
8 panencephalitis, subacute sclerosing 30.5 MAPT MBP MOG
9 dementia 30.5 APP BACE1 BDNF MAPT TBK1
10 acute disseminated encephalomyelitis 30.4 IL1B MBP MOG
11 hydrocephalus 30.4 APP GFAP MAPT MBP
12 spinal cord injury 30.3 BDNF GFAP MMP9 NOS2
13 encephalitis 30.3 GFAP IL1B MOG
14 ischemia 30.3 APP GFAP NOS2 TRPV1
15 tropical spastic paraparesis 30.3 CXCR3 IFNG MMP9
16 chlamydia 30.3 IFNG IL1B NOS2
17 allergic encephalomyelitis 30.2 MBP MOG
18 amyotrophic lateral sclerosis 1 30.2 APP BDNF GFAP MAPT TBK1
19 viral encephalitis 30.2 IL1B MBP MOG
20 mouth disease 30.2 IFNG IL1B TRPV1
21 neuritis 30.2 IFNG IL1B MBP MOG
22 prion disease 30.2 APP IL1B MAPT
23 brain injury 30.2 BDNF GFAP MAPT MBP
24 neuroblastoma 30.2 APP BACE1 BDNF H19 PROM1
25 synucleinopathy 30.1 APP GRM5 MAPT
26 sarcoidosis 1 30.1 CXCR3 IFNG IL1B
27 lymphadenitis 30.0 CXCR3 IFNG IL1B
28 traumatic brain injury 30.0 BDNF GFAP MBP
29 relapsing-remitting multiple sclerosis 30.0 BDNF IFNG MBP MMP9 MOG
30 peripheral nervous system disease 29.9 MBP MOG TRPV1
31 cerebral hemorrhage 29.8 APP GFAP IL1B
32 interstitial cystitis 29.8 BDNF CXCR3 TRPV1
33 brain edema 29.8 GFAP IL1B MMP9
34 multiple system atrophy 1 29.8 GFAP MAPT MBP
35 aphasia 29.8 APP BDNF MAPT
36 gliosarcoma 29.8 GFAP IFNG MMP9
37 autoimmune encephalitis 29.5 IFNG TRPV1
38 pediatric cns embryonal cell carcinoma 12.0
39 sjogren-larsson-like ichthyosis without cns or eye involvement 12.0
40 pediatric cns choriocarcinoma 12.0
41 optic atrophy with demyelinating disease of cns 12.0
42 arthrogryposis multiplex congenita cns calcification 12.0
43 ectodermal dysplasia intellectual disability cns malformation 12.0
44 melanocytic lesions of cns 12.0
45 retinopathy anemia cns anomalies 12.0
46 primary melanoma of the central nervous system 11.8
47 mismatch repair cancer syndrome 11.7
48 medulloblastoma 11.6
49 atypical teratoid rhabdoid tumor 11.6
50 crigler-najjar syndrome, type i 11.6

Graphical network of the top 20 diseases related to Central Nervous System Disease:



Diseases related to Central Nervous System Disease

Symptoms & Phenotypes for Central Nervous System Disease

UMLS symptoms related to Central Nervous System Disease:


headache, hemiplegia, hyperexplexia

MGI Mouse Phenotypes related to Central Nervous System Disease:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.38 APP BACE1 BDNF CCR1 CXCR3 GFAP
2 behavior/neurological MP:0005386 10.37 APP BACE1 BDNF GFAP GRM5 IFNG
3 growth/size/body region MP:0005378 10.37 APP BACE1 BDNF GFAP GRM5 IFNG
4 homeostasis/metabolism MP:0005376 10.34 APP BACE1 BDNF CCR1 CXCR3 GFAP
5 cardiovascular system MP:0005385 10.33 APP CCR1 CXCR3 GFAP IFNG IL1B
6 immune system MP:0005387 10.29 APP CCR1 CXCR3 GFAP IFNG IL1B
7 mortality/aging MP:0010768 10.28 APP BACE1 BDNF CCR1 CXCR3 GFAP
8 hematopoietic system MP:0005397 10.25 APP CCR1 CXCR3 IFNG IL1B MAPT
9 integument MP:0010771 10.2 APP BACE1 BDNF GRM5 IFNG IL1B
10 nervous system MP:0003631 10.17 APP BACE1 BDNF GFAP GRM5 IFNG
11 muscle MP:0005369 10.01 APP BACE1 GFAP IFNG MAPT MMP9
12 neoplasm MP:0002006 9.97 CXCR3 IFNG IL1B MAPT MMP9 NOS2
13 no phenotypic analysis MP:0003012 9.86 APP BACE1 BDNF IFNG MAPT PROM1
14 normal MP:0002873 9.81 APP BACE1 BDNF CXCR3 GFAP IFNG
15 renal/urinary system MP:0005367 9.56 CCR1 CXCR3 IFNG MAPT MMP9 NOS2
16 vision/eye MP:0005391 9.28 BDNF GFAP IFNG MAPT MBP MMP9

Drugs & Therapeutics for Central Nervous System Disease

Drugs for Central Nervous System Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1255)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
2
Sevoflurane Approved, Vet_approved Phase 4,Phase 2,Not Applicable 28523-86-6 5206
3
Propofol Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2078-54-8 4943
4
Clobazam Approved, Illicit Phase 4,Phase 3,Phase 2,Not Applicable 22316-47-8 2789
5
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 83-43-2 6741
6
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 302-25-0
7
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 50-24-8 5755
8
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 1,Phase 2 2921-57-5
9
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 84057-84-1 3878
10
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99-66-1 3121
11
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113775-47-6 68602 5311068
12
Dopamine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 51-61-6, 62-31-7 681
13
Levodopa Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1 59-92-7 6047
14
Mannitol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 69-65-8 453 6251
15
Midazolam Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 59467-70-8 4192
16
Morphine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 57-27-2 5288826
17
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 55142-85-3 5472
18
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 113665-84-2, 120202-66-6 60606
19
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
20
Curcumin Approved, Experimental, Investigational Phase 4 458-37-7 969516
21
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
22
Milnacipran Approved, Investigational Phase 4,Not Applicable 92623-85-3 65833
23
Ibuprofen Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 15687-27-1 3672
24
Acetylcholine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 51-84-3 187
25
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137-58-6 3676
26 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
28
Sufentanil Approved, Investigational Phase 4,Phase 2 56030-54-7 41693
29
Remifentanil Approved Phase 4,Phase 3,Not Applicable 132875-61-7 60815
30
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 113-45-1 4158
31
Glucosamine Approved, Investigational Phase 4,Phase 3,Not Applicable 3416-24-8 439213
32
Cilostazol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 73963-72-1 2754
33
Aspirin Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-78-2 2244
34
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 2 58-93-5 3639
35
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
36
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59729-33-8 2771
37
Huperzine A Approved, Experimental Phase 4,Phase 1,Phase 2,Not Applicable 102518-79-6
38
Candesartan cilexetil Approved Phase 4,Phase 2,Phase 3 145040-37-5 2540
39
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
40
Amphotericin B Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1397-89-3 5280965 14956
41
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22916-47-8 4189
42
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-02-2 5743
43
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1177-87-3
44
Lactulose Approved Phase 4,Phase 3,Phase 2,Not Applicable 4618-18-2 11333
45
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-66-6
46
Donepezil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 120014-06-4 3152
47
Memantine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 19982-08-2 4054
48
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 68291-97-4 5734
49
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 148553-50-8 5486971
50
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 6740-88-1 3821

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) Unknown status NCT01230580 Phase 4 Protease Inhibitor;Standard-of-care Antiretroviral therapy
2 Anesthesia Induction in Patients Undergoing Surgery for Cervical Myelopathy Unknown status NCT01052337 Phase 4 anaesthetics: sevofluorane
3 Effects of Perampanel on Cognition and Electroencephalography in Patients With Epilepsy Unknown status NCT02900755 Phase 4 Perampanel
4 Clobazam Adjunctive Treatment of Adults With Refractory Focal Epilepsy Unknown status NCT02726919 Phase 4 Clobazam
5 Immunotherapy in Intractable Cryptogenic Epilepsy Patients With Autoimmune Antibody Unknown status NCT02695797 Phase 4 Prednisolone
6 NIMIP: Non Invasive Measurement of the Intracranial Pressure Unknown status NCT01685450 Phase 4
7 The Impact of Reducing Overtreatment on Quality of Life in Children With Refractory Epilepsy Unknown status NCT00647322 Phase 4
8 Hormone Profiles in Adults With Newly Diagnosed Epilepsy Unknown status NCT00137709 Phase 4 Sodium valproate;Lamotrigine
9 Study to Improve the Treatment of Epilepsy (SITE) Unknown status NCT00133081 Phase 4 All registered antiepileptic drugs
10 Exoskeletons for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943669 Phase 4
11 Eyegaze Systems for Spinal Cord Injury: A Feasibility Study Unknown status NCT01943656 Phase 4
12 Consequence of Dexmedetomidine on Emergence Deliruim After Sevoflurane Anesthesia in Children With Cerebral Palsy Unknown status NCT02244515 Phase 4 dexmedetomidine
13 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
14 Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote Unknown status NCT00312676 Phase 4
15 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
16 A Clinical Trial of the Effect of Midazolam on the Cerebral Metabolism and Inflammatory Response in Patients With Moderate and Severe Traumatic Brain Injury Unknown status NCT02071407 Phase 4 Midazolam;Placebo
17 The CAPTAIN Trial: Cerebrolysin Asian Pacific Trial in Acute Brain Injury and Neurorecovery Unknown status NCT01606111 Phase 4 Cerebrolysin;0.9% NaCl, saline
18 Effect of Rozerem on Sleep Among People With Traumatic Brain Injury Unknown status NCT01207050 Phase 4 Ramelteon
19 Migraine Prophylaxis With Clopidogrel Trial Unknown status NCT02938182 Phase 4 clopidogrel
20 GON-block in Chronic Migraine: a Randomized, Double- Blind, Placebo-controlled Study Unknown status NCT02686983 Phase 4 Betamethasone and local anesthetic
21 The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients Unknown status NCT02532023 Phase 4
22 Occipital Transcutaneous Stimulation in Chronic Migraine Unknown status NCT02307071 Phase 4
23 Preventive Treatment of Episodic and Chronic Migraine Unknown status NCT01319825 Phase 4 milnacipran
24 A Double-blind, Placebo-controlled Pilot Study to Collect and Evaluate Data on the Use of Intravenous Ibuprofen in the Treatment of an Acute Migraine Attack Unknown status NCT01230411 Phase 4 Ibuprofen
25 American Migraine Prevention Study Unknown status NCT00363506 Phase 4
26 Botox for Neurogenic Detrusor Overactivity and the Prevention of Autonomic Dysreflexia Following SCI Unknown status NCT02298660 Phase 4 BOTOX
27 The Effect of Dexmedetomidine to Cognition of Geriatrics in Prolonged Surgery Unknown status NCT02123355 Phase 4 Induction of anesthesia;Sevoflurane, remifentanil ,vecuronium;Dexmedetomidine;Placebo
28 Methylphenidate for Attention Problems After Pediatric TBI Unknown status NCT01933217 Phase 4 Methylphenidate;Placebo
29 Effects of Cerebrolysin Combined With Rehabilitation on Motor Recovery in Stroke Unknown status NCT02768571 Phase 4 Cerebrolysin;Placebo
30 Effectiveness and Safety of Yiqitongluo Granule for Stroke Unknown status NCT02604654 Phase 4 Yiqitongluo granule
31 The Safety and Efficacy Study of High Dose Atorvastatin After Thrombolytic Treatment in Acute Ischemic Stroke Unknown status NCT02452502 Phase 4
32 4-point vs 4-roll Canne as Walking Aids After Stroke Unknown status NCT02279069 Phase 4
33 A Clinical Trial of Danhong Injection in Treating Acute Ischemic Stroke Unknown status NCT02152280 Phase 4 Danhong Injection;Normal Saline
34 FINGER Robot Therapy Study Unknown status NCT02048826 Phase 4
35 Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease Unknown status NCT01932203 Phase 4 aspirin;cilostazol
36 Stratification of Blood Pressure Control Against Progress of Cerebral Small Vessel Diseases in Poststroke Patients Unknown status NCT01819441 Phase 4 Azelnidipine;Perindopril;hydrochlorothiazide
37 Creative Therapy to Affect Stroke Outcomes Unknown status NCT01455155 Phase 4
38 Assess the Penumbra System in the Treatment of Acute Stroke Unknown status NCT01429350 Phase 4 intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
39 Effects on Clinical and Functional Outcome of Escitalopram in Adult Stroke Patients Unknown status NCT00967408 Phase 4 Escitalopram;Placebo
40 Functional Electrical Stimulation (FES) Assisted Walking: Enhancement of Walking Function After Stroke Unknown status NCT00552916 Phase 4
41 Early Warning and Optimization Strategy in Carotid Endarterectomy Unknown status NCT01210937 Phase 4
42 Huperzine-A to Help With Mental Problems and the Inability to Care for Onself in Patients With Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
43 Acute Candesartan Cilexetil Outcomes Stroke Trial (ACCOST) Unknown status NCT00108706 Phase 4 Candesartan
44 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
45 Efficacy and Safety of DBS of the GPi in Patients With Primary Generalized and Segmental Dystonia Unknown status NCT00142259 Phase 4
46 Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis Unknown status NCT02686853 Phase 4 Liposomal amphotericin B
47 The Relationships Between Gene Polymorphisms of LTA4H and Dexamethasone Treatment for Tuberculous Meningitis Unknown status NCT02588196 Phase 4 Dexamethasone acetate
48 Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients Unknown status NCT03004209 Phase 4 Erythropoietin
49 Trial Comparing Sedation for Endoscopy With Propofol Versus Midazolam in Cirrhotics Unknown status NCT01356121 Phase 4 Propofol;Midazolam
50 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)

Search NIH Clinical Center for Central Nervous System Disease

Cochrane evidence based reviews: central nervous system diseases

Genetic Tests for Central Nervous System Disease

Anatomical Context for Central Nervous System Disease

MalaCards organs/tissues related to Central Nervous System Disease:

41
Brain, Spinal Cord, Bone, Testes, T Cells, Myeloid, Skin

Publications for Central Nervous System Disease

Articles related to Central Nervous System Disease:

(show top 50) (show all 439)
# Title Authors Year
1
Predicting the incidence and timing of central nervous system disease in metastatic melanoma: Implications for surveillance and preventative therapy. ( 29332716 )
2018
2
Infliximab-Associated Chronic Inflammatory Central Nervous System Disease and Peroneal Nerve Injury in a Psoriatic Patient Refractory to Treatment: Case Report with 10-Year Follow-Up. ( 29515419 )
2018
3
A matrix metalloproteinase 9 (MMP9) gene single nucleotide polymorphism is associated with predisposition to tick-borne encephalitis virus-induced severe central nervous system disease. ( 29496490 )
2018
4
Stem cells in the treatment of central nervous system disease. ( 29523970 )
2018
5
Unraveling of Central Nervous System Disease Mechanisms Using CRISPR Genome Manipulation. ( 30013417 )
2018
6
Rat Lungworm Infection Associated with Central Nervous System Disease - Eight U.S. States, January 2011-January 2017. ( 30070981 )
2018
7
MicroRNAs of microglia: Wrestling with central nervous system disease. ( 30323123 )
2018
8
Testing for Bartonella ssp. DNA in cerebrospinal fluid of dogs with inflammatory central nervous system disease. ( 30381844 )
2018
9
Adenovirus-Associated Central Nervous System Disease in Children. ( 30413311 )
2018
10
Potential widespread denitrosylation of brain proteins following prolonged restraint: proposed links between stress and central nervous system disease. ( 30414012 )
2018
11
Mycophenolate mofetil in the treatment of pediatric autoimmune central nervous system disease. ( 30474195 )
2018
12
Case report of neurotoxicity with blinatumomab and concurrent intrathecal chemotherapy in second relapse of acute lymphoblastic leukemia with central nervous system disease. ( 30537919 )
2018
13
Treatment of Epstein-Barr virus associated central nervous system diseases after allogeneic hematopoietic stem cell transplantation with intrathecal donor lymphocyte infusion. ( 30518982 )
2018
14
Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases. ( 29380517 )
2018
15
Central nervous system diseases and Scutellaria: a review of current mechanism studies. ( 29554597 )
2018
16
The Role of IRE1 Signaling in the Central Nervous System Diseases. ( 29663887 )
2018
17
Non-covalent Small-Molecule Kelch-like ECH-Associated Protein 1-Nuclear Factor Erythroid 2-Related Factor 2 (Keap1-Nrf2) Inhibitors and Their Potential for Targeting Central Nervous System Diseases. ( 29750408 )
2018
18
Macrophages as Nanocarriers for Drug Delivery: Novel Therapeutics for Central Nervous System Diseases. ( 29768873 )
2018
19
Physiological Roles of Metallothioneins in Central Nervous System Diseases. ( 29962397 )
2018
20
Nanoparticle crossing of blood-brain barrier: a road to new therapeutic approaches to central nervous system diseases. ( 29998779 )
2018
21
3D double inversion recovery MR imaging: Clinical applications and usefulness in a wide spectrum of central nervous system diseases. ( 30016704 )
2018
22
Applications of carbonic anhydrases inhibitors in renal and central nervous system diseases. ( 30175635 )
2018
23
A Review of Stem Cell Therapy for Acquired Brain Injuries and Neurodegenerative Central Nervous System Diseases. ( 30269801 )
2018
24
The Gut-Microglia Connection: Implications for Central Nervous System Diseases. ( 30344525 )
2018
25
Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. ( 28933846 )
2017
26
Occupational exposure to extremely low-frequency magnetic fields and risk for central nervous system disease: an update of a Danish cohort study among utility workers. ( 28429106 )
2017
27
Is the Eye an Extension of the Brain in Central Nervous System Disease? ( 28609158 )
2017
28
Central Nervous System Disease in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis. ( 29061243 )
2017
29
Central nervous system disease in pediatric acute myeloid leukemia. ( 28853216 )
2017
30
Immunotherapeutics in Pediatric Autoimmune Central Nervous System Disease: Agents and Mechanisms. ( 29103429 )
2017
31
Metabolic Profiling of Central Nervous System Disease in Trypanosoma brucei rhodesiense infection. ( 28927234 )
2017
32
Production of transgenic pigs using the<i>pGFAP-CreER<sup>T2</sup>;EGFP<sup>LoxP</sup></i>inducible system for central nervous system disease models. ( 29284207 )
2017
33
Central Nervous System Disease, Education, and Race Impact Radiation Refusal in Pediatric Cancer Patients. ( 28538508 )
2017
34
Central nervous system disease in pediatric acute myeloid leukemia: A report from the Children's Oncology Group. ( 28453910 )
2017
35
Cerebrospinal fluid pleocytosis in infectious and noninfectious central nervous system disease: A retrospective cohort study. ( 28471963 )
2017
36
Wasp Venom Immunotherapy in a Patient With Immune-Mediated Inflammatory Central Nervous System Disease: Is it Safe? ( 28398199 )
2017
37
Editorial: Induction of Central Nervous System Disease by the Adaptive Immune Response. ( 29038655 )
2017
38
Highly Expandable Human iPS Cell-Derived Neural Progenitor Cells (NPC) and Neurons for Central Nervous System Disease Modeling and High-Throughput Screening. ( 28075486 )
2017
39
Gpr124 is essential for blood-brain barrier integrity in central nervous system disease. ( 28288111 )
2017
40
Current Understanding of Platelet-Activating Factor Signaling in Central Nervous System Diseases. ( 27613281 )
2017
41
Protective roles of melatonin in central nervous system diseases by regulation of neural stem cells. ( 27943459 )
2017
42
Progress and promise of antisense oligonucleotide therapeutics for central nervous system diseases. ( 27998711 )
2017
43
Preventive and Protective Roles of Dietary Nrf2 Activators Against Central Nervous System Diseases. ( 28042770 )
2017
44
Combination of RNA Interference and Stem Cells for Treatment of Central Nervous System Diseases. ( 28481269 )
2017
45
Neuroprotective Effects of Drug-Induced Therapeutic Hypothermia in Central Nervous System Diseases. ( 28595536 )
2017
46
Functional Expression of Organic Ion Transporters in Astrocytes and Their Potential as a Drug Target in the Treatment of Central Nervous System Diseases. ( 28768996 )
2017
47
Three-Dimensional Organoid System Transplantation Technologies in Future Treatment of Central Nervous System Diseases. ( 28904534 )
2017
48
Neuro-Coagulopathy: Blood Coagulation Factors in Central Nervous System Diseases. ( 29023416 )
2017
49
α-Lipoic acid, functional fatty acid, as a novel therapeutic alternative for central nervous system diseases: A review. ( 29185388 )
2017
50
Central nervous system disease and genital disease in harbor porpoises (Phocoena phocoena) are associated with different herpesviruses. ( 26861818 )
2016

Variations for Central Nervous System Disease

Expression for Central Nervous System Disease

Search GEO for disease gene expression data for Central Nervous System Disease.

Pathways for Central Nervous System Disease

Pathways related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1 12.33 APP BACE1 GFAP GRM5 MAPT MBP
2
Show member pathways
12.17 IFNG IL1B MMP9 TBK1
3 11.73 IFNG IL1B NOS2
4 11.67 IFNG IL1B NOS2
5
Show member pathways
11.65 APP GRM5 IFNG IL1B MMP9
6 11.63 CXCR3 IFNG IL1B
7 11.57 BDNF GFAP MOG PROM1
8 11.44 APP BACE1 GRM5
9 11.42 APP BACE1 MAPT
10
Show member pathways
11.36 IFNG IL1B MMP9 NOS2
11 11.35 IFNG IL1B NOS2
12 11.31 APP BACE1 MAPT
13 11.25 BDNF GFAP IFNG IL1B MBP MMP9
14 11.2 IFNG IL1B NOS2
15 11.2 BDNF IFNG IL1B MMP9 NOS2
16 11.01 IFNG IL1B MMP9
17 10.94 APP BACE1 MMP9

GO Terms for Central Nervous System Disease

Cellular components related to Central Nervous System Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.8 APP BACE1 CCR1 CXCR3 GRM5 PROM1
2 astrocyte projection GO:0097449 9.16 APP GFAP
3 glial cell projection GO:0097386 8.96 GFAP MAPT
4 main axon GO:0044304 8.62 APP MAPT

Biological processes related to Central Nervous System Disease according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 9.99 CCR1 CXCR3 IFNG IL1B MBP
2 cytokine-mediated signaling pathway GO:0019221 9.91 CCR1 IL1B MMP9 NOS2
3 cell surface receptor signaling pathway GO:0007166 9.9 CCR1 CXCR3 IFNG TRPV1
4 inflammatory response GO:0006954 9.89 CCR1 CXCR3 IL1B TBK1 TRPV1
5 positive regulation of protein phosphorylation GO:0001934 9.81 APP IFNG IL1B MMP9
6 positive regulation of cytosolic calcium ion concentration GO:0007204 9.78 CCR1 CXCR3 IL1B TRPV1
7 memory GO:0007613 9.76 BDNF IL1B MAPT
8 regulation of insulin secretion GO:0050796 9.72 IFNG IL1B NOS2
9 synapse organization GO:0050808 9.63 APP GRM5 MAPT
10 axon development GO:0061564 9.62 GFAP MAPT
11 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG IL1B
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 IFNG IL1B TRPV1
13 astrocyte activation GO:0048143 9.58 APP MAPT
14 amyloid fibril formation GO:1990000 9.57 APP MAPT
15 cellular response to manganese ion GO:0071287 9.56 APP BACE1
16 modulation of age-related behavioral decline GO:0090647 9.54 APP GRM5
17 cellular response to nerve growth factor stimulus GO:1990090 9.54 APP MAPT TRPV1
18 positive regulation of receptor binding GO:1900122 9.52 BDNF MMP9
19 positive regulation of killing of cells of other organism GO:0051712 9.4 IFNG NOS2
20 cellular response to amyloid-beta GO:1904646 9.33 APP BACE1 GRM5
21 fever generation GO:0001660 9.32 IL1B TRPV1
22 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG IL1B
23 response to lead ion GO:0010288 9.13 APP BACE1 MAPT
24 negative regulation of gene expression GO:0010629 9.1 APP CCR1 IFNG MAPT NOS2 TBK1

Sources for Central Nervous System Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....